KLF4 Initiates Dedifferentiation of Systemic Sclerosis Lung Fibroblasts
Cells · 18.05.2026 · 15 (10) · 921
DOI: 10.3390/cells15100921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 18.05.2026. Verfasst von Ludivine Renaud und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 822, Charlesto…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Fibroblasts, Cell Dedifferentiation, Lung. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, SmartState Center for Inflammation and Fibrosis Research at the Medical University of South Carolina.
Abstract (Originalsprache)
Background
Systemic sclerosis (SSc) is a systemic autoimmune disease leading to extensive fibrosis of the skin and many visceral organs, including the lungs. The need for effective treatments is urgent, as none exists today that can stop or reverse the progression of fibrosis. We examined the effect of restoring KLF4 levels in primary human lung fibroblasts of SSc patients with pulmonary fibrosis as a potential therapeutic strategy.
Methods
We restored KLF4 levels in SSc lung fibroblasts by adenoviral infection and extracted total RNA for RNA sequencing. Genes and systems level analyses were performed, and selected genes of interest and markers of alveolar, inflammatory, and fibrotic fibroblasts were further validated at the mRNA and protein levels.
Results
Our results showed that restoring KLF4 levels in SSc lung fibroblasts initiated dedifferentiation of αSMA and CTHRC1, expressing myofibroblasts by repressing markers of inflammatory and fibrotic fibroblasts while boosting markers of alveolar fibroblasts. Our data also revealed that restoring KLF4 levels prevented TGFβ1-induced fibrogenesis in normal lung fibroblasts, and reduced fibrosis in explanted human lungs in organ culture.
Conclusions
Our results in human primary SSc lung fibroblasts showed that restoring KLF4 levels initiated dedifferentiation of fibrotic and inflammatory fibroblasts towards the phenotype of alveolar fibroblasts, their lineage precursors, highlighting the potential of KLF4 as a therapy to stop and reverse fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 822, Charleston, SC 29425, USA.
- Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 816, Charleston, SC 29425, USA.
ORCID-Profile: Ludivine Renaud, Aravind Menon, Carol Feghali-Bostwick
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- SmartState Center for Inflammation and Fibrosis Research at the Medical University of South Carolina
- IPF Foundation
Zitieren
APA
Renaud, L., Kotz, S., Menon, A., & Feghali-Bostwick, C. (2026). KLF4 Initiates Dedifferentiation of Systemic Sclerosis Lung Fibroblasts. Cells, 15(10), 921. https://doi.org/10.3390/cells15100921
Vancouver
Renaud L, Kotz S, Menon A, Feghali-Bostwick C. KLF4 Initiates Dedifferentiation of Systemic Sclerosis Lung Fibroblasts. Cells. 2026;15(10):921. doi:10.3390/cells15100921
BibTeX
@article{Renaud2026,
author = {Renaud, Ludivine and Kotz, Samantha and Menon, Aravind and Feghali-Bostwick, Carol},
title = {KLF4 Initiates Dedifferentiation of Systemic Sclerosis Lung Fibroblasts},
journal = {Cells},
year = {2026},
volume = {15},
number = {10},
pages = {921},
doi = {10.3390/cells15100921}
}
EUVIMED